HUP0300627A2 - Terápiára alkalmas szintetikus oligonukleotidok - Google Patents

Terápiára alkalmas szintetikus oligonukleotidok

Info

Publication number
HUP0300627A2
HUP0300627A2 HU0300627A HUP0300627A HUP0300627A2 HU P0300627 A2 HUP0300627 A2 HU P0300627A2 HU 0300627 A HU0300627 A HU 0300627A HU P0300627 A HUP0300627 A HU P0300627A HU P0300627 A2 HUP0300627 A2 HU P0300627A2
Authority
HU
Hungary
Prior art keywords
synthetic oligonucleotides
gxty
tygx
therapeutically useful
useful synthetic
Prior art date
Application number
HU0300627A
Other languages
English (en)
Inventor
Mario C. Filion
Nigel C. Phillips
Original Assignee
Bioniche Life Sciences Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Life Sciences Inc. filed Critical Bioniche Life Sciences Inc.
Publication of HUP0300627A2 publication Critical patent/HUP0300627A2/hu
Publication of HUP0300627A3 publication Critical patent/HUP0300627A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A találmány tárgyát 2--20 bázis méretű 3'-OH, 5'-OH szintetikusoligonukleotidokat (szekvenciákat) tartalmazó készítmények éseljárások képezik, amelyekben a szintetikus oligonukleotidok lehetnek(GxTy)n (I), (TyGx) n (II), a (GxTy)n, (III), (GxTy)nb (IV), (TyGx)nb(V), a(GxTy)nb (VI), a(TyGx)nb (VII) összetételűek, ahol a képletekbenx és y értéke 1-7, bármely egész szám, n értéke 1-12. bármely egészszám, továbbá a és b jelentése egy vagy több A, C, G vagy T, és amelyszekvenciák a sejtciklus megállítását, sejtosztódás gátlását,kaszpázok aktiválását, rákos sejtekben az apoptózist vagy azimmunrendszer sejtjeiben citokinek előállítását indukálják. Ó
HU0300627A 1999-12-13 2000-12-12 Therapeutically useful synthetic oligonucleotides HUP0300627A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17032599P 1999-12-13 1999-12-13
US22892500P 2000-08-29 2000-08-29
PCT/CA2000/001467 WO2001044465A2 (en) 1999-12-13 2000-12-12 Therapeutically useful synthetic oligonucleotides

Publications (2)

Publication Number Publication Date
HUP0300627A2 true HUP0300627A2 (hu) 2004-06-28
HUP0300627A3 HUP0300627A3 (en) 2005-11-28

Family

ID=26865979

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300627A HUP0300627A3 (en) 1999-12-13 2000-12-12 Therapeutically useful synthetic oligonucleotides

Country Status (18)

Country Link
US (2) US7157436B2 (hu)
EP (2) EP1238070B1 (hu)
JP (1) JP4772245B2 (hu)
KR (1) KR100829646B1 (hu)
CN (2) CN100445380C (hu)
AT (2) ATE455851T1 (hu)
AU (1) AU785212B2 (hu)
CA (1) CA2393808A1 (hu)
CZ (1) CZ20022372A3 (hu)
DE (2) DE60036019T2 (hu)
DK (2) DK1867718T3 (hu)
ES (2) ES2288883T3 (hu)
HU (1) HUP0300627A3 (hu)
IL (2) IL150196A0 (hu)
MX (1) MXPA02005842A (hu)
NO (1) NO330508B1 (hu)
PT (1) PT1238070E (hu)
WO (1) WO2001044465A2 (hu)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032610A1 (en) 1996-06-03 2003-02-13 Gilchrest Barbara A. Method to inhibit cell growth using oligonucleotides
US7960540B2 (en) 1999-04-08 2011-06-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US8114850B2 (en) 1999-04-08 2012-02-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
PT1181304E (pt) 1999-04-08 2008-01-23 Antisoma Res Ltd Actividade antiproliferativa de oligonucleótidos ricos em g e método de utilização dos mesmos para ligação a nucleolina
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
IL150196A0 (en) * 1999-12-13 2002-12-01 Bioniche Life Sciences Inc Therapeutically useful synthetic oligonucleotides
MXPA03001812A (es) 2000-08-29 2004-05-21 Bioniche Life Sciences Inc Modulacion de la expresion del sindrome de alcohol fetal y del ligando del sindrome de alcohol fetal..
ES2307568T3 (es) * 2000-12-08 2008-12-01 Coley Pharmaceutical Gmbh Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
US7087586B2 (en) * 2001-04-24 2006-08-08 Bioniche Life Sciences, Inc. Oligonucleotide compositions and their use to induce differentiation of cells
KR101017483B1 (ko) * 2001-08-17 2011-02-25 바이오니취 라이프 사이언시즈 인코포레이티드 올리고뉴클레오타이드 조성물 및 세포사멸을 유도하기위한 그의 용도
AU2002341264B2 (en) * 2001-10-03 2007-07-12 Bioniche Life Sciences Inc. Therapeutically useful triethyleneglycol cholesteryl oligonucleotides
CA2483012C (en) * 2002-04-22 2011-05-24 Bioniche Life Sciences Inc. Oligonucleotide compositions and their use for the modulation of immune responses
CA2521050A1 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
KR20060012622A (ko) * 2003-05-16 2006-02-08 하이브리돈, 인코포레이티드 화학요법제와 함께 이뮤노머를 사용하는 상승적 암 치료방법
JP2008531018A (ja) * 2005-02-24 2008-08-14 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫刺激性オリゴヌクレオチド
CA2600440A1 (en) * 2005-03-09 2006-09-21 Baylor College Of Medicine Direct reversal of the suppressive function of cd4+ regulatory t cells via toll-like receptor 8 signaling
WO2007028985A2 (en) * 2005-09-07 2007-03-15 The Secretary Of State For Defence Adjuvanted vaccine
WO2010093906A2 (en) * 2009-02-12 2010-08-19 Curna, Inc. Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
KR100998365B1 (ko) 2009-06-29 2010-12-06 압타바이오 주식회사 치료 효능이 있는 변형핵산 및 구아노신을 함유하는 올리고뉴클레오티드 변형체
TW201102073A (en) * 2009-07-15 2011-01-16 Enzon Pharmaceuticals Inc RNA antagonists targeting GLI2 for the treatment of leukemia
CN104520439A (zh) * 2012-02-28 2015-04-15 国立大学法人东京农工大学 Tdp-43细胞内存在量关联疾患的认定方法
EP4000597A1 (en) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptide and compositions comprising tetrapeptides
WO2023122762A1 (en) * 2021-12-22 2023-06-29 Camp4 Therapeutics Corporation Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172815A (en) * 1962-04-24 1965-03-09 Warner Lambert Pharmaceutical Method for preparing reticulo-endo-thelial system stimulant and stimulant thereof
US4152423A (en) * 1971-11-19 1979-05-01 Agence Nationale De Valorisation De La Recherche (Anvar) Immunological agents
FR2160326B1 (hu) * 1971-11-19 1975-02-07 Anvar
CA1020460A (en) * 1973-02-23 1977-11-08 Wellcome Foundation Limited (The) Isolation of immunostimulating glycopeptide from bacteria
US3976544A (en) * 1973-06-19 1976-08-24 The Agence Nationale De Valorisation De Le Recherche Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction
FR2374042A1 (fr) * 1976-06-04 1978-07-13 Merieux Inst Nouveau medicament immunostimulant et son procede de preparation
JPS54140710A (en) * 1978-03-10 1979-11-01 Mitsui Toatsu Chem Inc Anti-tumor substance and its preparation
DE3011461C2 (de) * 1980-03-25 1986-10-30 Dr. Madaus & Co, 5000 Köln Verwendung von Propionibakterien
US4520019A (en) * 1982-04-29 1985-05-28 Ribi Immunochem Research, Inc. Stable composition and preparation thereof
US4579941A (en) * 1982-08-13 1986-04-01 Mitsuitoatsu Chemicals, Inc. Thermally-denatured deoxyribonucleic acid MD-011 and antitumor agent
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
US4744984A (en) * 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
DE3723075A1 (de) * 1987-07-11 1989-01-19 Boehringer Mannheim Gmbh Eukaryotische expressionsvektoren mit multimeren enhancer-subelementen, verfahren zu ihrer herstellung und verwendung
US4958013A (en) * 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
WO1992007095A1 (en) * 1990-10-15 1992-04-30 Stratagene Arbitrarily primed polymerase chain reaction method for fingerprinting genomes
IL101038A0 (en) * 1991-02-21 1992-11-15 Gilead Sciences Inc Agent specific for trombin and its use
EP0952855B1 (en) * 1991-07-03 2005-07-27 Meditech Research Limited Use of hyaluronan in gene therapy
US5582981A (en) * 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
IL107150A0 (en) * 1992-09-29 1993-12-28 Isis Pharmaceuticals Inc Oligonucleotides having a conserved g4 core sequence
CN1102855C (zh) * 1993-01-29 2003-03-12 维特里制药有限公司 免疫治疗组合物
US5567604A (en) * 1993-04-23 1996-10-22 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
CN1154702A (zh) * 1994-05-25 1997-07-16 海布里登公司 具有抗巨细胞病毒活性的寡核苷酸
DE69533037T2 (de) * 1994-08-30 2005-05-04 Commonwealth Scientific And Industrial Research Organisation Pflanzentraskriptionsregulator von circovirus
US5643890A (en) 1995-01-31 1997-07-01 The Board Of Regents Of The University Of Nebraska Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
IN181358B (hu) * 1995-02-14 1998-05-30 Bioniche Inc
ZA964446B (en) * 1995-06-06 1996-12-06 Hoffmann La Roche Oligonucleotides specific for hepatitis c virus
US5990299A (en) * 1995-08-14 1999-11-23 Icn Pharmaceuticals, Inc. Control of CD44 gene expression for therapeutic use
KR19990071523A (ko) * 1995-11-21 1999-09-27 해리 에이. 루스제 Il－8 및 il－8 수용체에 대한 안티센스올리고누클레오티드에 의한 종양 성장의 억제방법
IT1277025B1 (it) * 1995-12-04 1997-11-04 Cooperativa Centro Ricerche Po Classe di oligonucleotidi fosfodiesterici ad attivita' citotossica composizioni farmaceutiche che li contengono e loro uso
US6015710A (en) * 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
US6316190B1 (en) * 1996-05-20 2001-11-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Oligonucleotides which specifically bind retroviral nucleocapsid proteins
EP1003525B1 (en) * 1997-08-05 2002-11-20 Bioniche Life Sciences Inc. Composition and method for regulating cell proliferation and cell death
US6255473B1 (en) * 1997-08-29 2001-07-03 Duke University Presenilin-1 gene promoter
MXPA02003108A (es) * 1999-09-25 2003-10-14 Univ Iowa Res Found Acidos nucleicos inmunoestimuladores.
IL150196A0 (en) * 1999-12-13 2002-12-01 Bioniche Life Sciences Inc Therapeutically useful synthetic oligonucleotides
US20020091095A1 (en) * 1999-12-13 2002-07-11 Phillips Nigel C. Modulation of Fas and FasL expression
US7125858B2 (en) * 1999-12-28 2006-10-24 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
AU2002341264B2 (en) * 2001-10-03 2007-07-12 Bioniche Life Sciences Inc. Therapeutically useful triethyleneglycol cholesteryl oligonucleotides
CA2483012C (en) * 2002-04-22 2011-05-24 Bioniche Life Sciences Inc. Oligonucleotide compositions and their use for the modulation of immune responses

Also Published As

Publication number Publication date
PT1238070E (pt) 2007-11-06
JP2003517041A (ja) 2003-05-20
EP1867718B1 (en) 2010-01-20
CN101491536B (zh) 2012-07-04
NO20022820L (no) 2002-08-08
EP1867718A3 (en) 2008-04-02
ATE455851T1 (de) 2010-02-15
WO2001044465A2 (en) 2001-06-21
CN101491536A (zh) 2009-07-29
DE60043759D1 (de) 2010-03-11
ES2340807T3 (es) 2010-06-09
IL150196A0 (en) 2002-12-01
JP4772245B2 (ja) 2011-09-14
AU1847901A (en) 2001-06-25
NO330508B1 (no) 2011-05-09
NO20022820D0 (no) 2002-06-13
CN100445380C (zh) 2008-12-24
CA2393808A1 (en) 2001-06-21
DE60036019T2 (de) 2008-05-29
AU785212B2 (en) 2006-11-09
ATE370231T1 (de) 2007-09-15
CN1433469A (zh) 2003-07-30
EP1238070B1 (en) 2007-08-15
ES2288883T3 (es) 2008-02-01
US20010041681A1 (en) 2001-11-15
KR100829646B1 (ko) 2008-05-16
DE60036019D1 (de) 2007-09-27
EP1867718A2 (en) 2007-12-19
HUP0300627A3 (en) 2005-11-28
MXPA02005842A (es) 2003-10-14
DK1238070T3 (da) 2007-12-03
CZ20022372A3 (cs) 2002-11-13
IL150196A (en) 2009-06-15
DK1867718T3 (da) 2010-04-12
US7157436B2 (en) 2007-01-02
KR20020079752A (ko) 2002-10-19
US20070213291A1 (en) 2007-09-13
EP1238070A2 (en) 2002-09-11
WO2001044465A3 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
HUP0300627A2 (hu) Terápiára alkalmas szintetikus oligonukleotidok
HU9501963D0 (en) 7-deazapurine modified oligonucleotides
DE69012141D1 (de) Ortsspezifische modifikation des candida tropicalis genomes.
NO20002113D0 (no) Nye tricykliske forbindelser og deres anvendelse i medisin, fremgangsmÕte for deres fremstillling og farmasøytiske sammensetninger inneholdende dem
FI925174A (fi) Nya organokiselfoereningar och kompositioner innehaollande dem
IT230897Y1 (it) Struttura anulare per articoli di gioielleria, oreficeria, bigiotteria o simili, in special modo per anelli.
ATE190352T1 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
NO304384B1 (no) Al-Sr-Si-B-forlegering, fremgangsmÕte for dens fremstilling og anvendelse av forlegeringen
DK0567648T3 (da) Afkølingsresistente planter og produktion deraf
IT8883457A0 (it) Impianto di laminazione prodotti piani
IT1239667B (it) Gruppo combinato di raddrizzatura e linearizzazione profilati
DE3854388D1 (de) Beschichtete polykristalline diamantkörper, produkte und ihre herstellung.
IT1241123B (it) Cellule umane per l'elevata espressione di geni inseriti in dna ricombinanti episomiali,loro preparazione e loro impiego
ITMI921235A1 (it) Oligonucleotidi antisenso ad attivita' antitumorale, composizioni farmaceutiche che li comprendono, e loro impieghi
DK22391D0 (da) Rekombinant-dna-molekyle og plantetransformationsvektor med overtraeksproteingenet fra agurkemosaikvirus, bakterie- og planteceller indeholdende dem samt saadanne planters produktion
ES466057A1 (es) Un procedimiento para preparar compuestos de 4"-desoxi-4"- amino-eritromicina a.
IT8983483A0 (it) Gruppo combinato di raddrizzatura e linearizzazione profilati
IT1247510B (it) Composizioni terapeutiche ad attivita' anti-hiv costituite da 2',3'-didesossiadenosina e sostanze inibitrici della adenosina-deaminasi
ITBA910005U1 (it) Serie di appoggi per fornelloni destinati ad uso combinato o singolo.
JPS53137767A (en) Decorative article
ITRE930088A1 (it) Impianto ad elevata produttivita' per la fabbricazione di piastrelle ceramiche in genere
ITRM930690A1 (it) Articolo anulare di oreficeria o di bigiotteria, ad elementi componibili.
IT8052950V0 (it) Vasi, portavasi ed elementi decorativi assimilabili aventi sulle pareti esterne incavi ed incisioni oppur unamente modificate, adatte al trapianto di muschi oppur di piccole piante
DK12292D0 (da) Syntese af vigtigt nucleosid, der kan bruges i syntesen af 2',3'-dideoxynucleosider
IT8323593A0 (it) Articolo ceramico di colore oro, duro, decorativo.

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished